Bothell-based CMC Biologics, a manufacturer of therapeutic proteins, and Genexine, a disease-focused South Korean biotech company, recently entered a manufacturing agreement for Genexines’s next-generation, long-acting human growth hormone drug, GX-H9.

Genexine said it selected CMC Biologics as its partner due to the Bothell company’s technical expertise and high-quality operations.

“The successful transfer and manufacture of GX-H9 is critical to meeting our clinical timelines as we advance our lead candidate towards a pivotal study and we believe that CMC can take us there,” Genexine president and CEO Dr. Michael Keyoung said in a press release.

Human growth hormone is responsible for promoting the healthy growth and development of the human body. Genexine’s GX-H9 currently is being evaluated as a weekly and twice-monthly dosing regimen for treating Growth Hormone Deficiency in both adults and children.

“As human growth hormone plays a critical role in the human metabolic system, GX-H9 will be critical for both children and adults with hormone deficiency to receive this drug,” Gustavo Mahler, global chief executive officer and president of CMC Biologics said in a press release. “We are very excited to be working with Genexine, to help these patients potentially live their lives as normal as possible after treatment.”